Pompe disease treatment

27 October 2016

Based on recent available evidence, NZORD supports the listing of alglucosidase alfa (Myozyme) for patients with infantile Pompe disease from 1 December 2016. However, we also recommend that late-onset Pompe disease (LOPD) treatment be funded.

Read our full position in our submission to PHARMAC.

Katie Archer